---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000004"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:19:18.992054+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere plans sNDA for FILSPARI in FSGS after FDA Type C meeting

## Summary
- Completed Type C meeting with FDA; sNDA seeking traditional approval for FILSPARI in FSGS expected by end of Q1 2025.
- sNDA will rely on existing Phase 3 DUPLEX and Phase 2 DUET study data for FILSPARI.
- PARASOL workgroup findings show proteinuria reduction over 24 months strongly linked to lower kidney failure risk in FSGS.
- If approved, FILSPARI could become first and only approved therapy indicated for FSGS, a rare kidney disorder.

## SEC filing metadata
- accession: 0001438533-25-000004
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000004/0001438533-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000004/tvtx-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000004
- JSON: https://secwatch.observer/filing/0001438533-25-000004.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.